TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05545059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
Study: NCT05711394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Matching Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Matching Atogepant
Description: Oral Tablet
Study: NCT06020274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program
Description: The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
Study: NCT05687994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiovisual Speech Entrainment Practice
Description: Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiovisual Speech Entrainment Practice
Description: Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Speech Entrainment Practice
Description: Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Speech Entrainment Practice
Description: Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
Study: NCT05304182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYESTAR 900
Description: The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYESTAR 900
Description: The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LENSTAR LS 900
Description: The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LENSTAR LS 900
Description: The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'.
Study: NCT05345171

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX301
Description: non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX301
Description: non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Participants who receive DTX301 solution will receive oral corticosteroids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroids
Description: Participants who receive DTX301 solution will receive oral corticosteroids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for oral corticosteroids
Description: Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for oral corticosteroids
Description: Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate
Description: A tracer for the Ureagenesis Rate Test (URT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Acetate
Description: A tracer for the Ureagenesis Rate Test (URT)
Study: NCT06503354

Intervention type: DEVICE
Intervention: Neural Sleeve and Zeno walkway
Description: A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.
Study: NCT05138926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Manipulation
Description: high speed, low amplitude cervical manipulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Cervical Manipulation
Description: Cervical mobilization without performing spinal manipulation
Study: NCT05106387

Intervention type: OTHER
Intervention: Noninterventional
Description: No investigational treatment will be given in this noninterventional extension study
Study: NCT04534543

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI/Spectroscopy
Description: Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
Study: NCT06637163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy
Description: Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
Study: NCT04729621

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TVB-009
Description: TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TVB-009
Description: TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TVB-009
Description: TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prolia®
Description: Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Study: NCT06045780

Intervention type: OTHER
Intervention: nothing
Description: disease

Intervention type: OTHER
Intervention: nothing
Description: disease
Study: NCT05212922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001 + Toripalimab
Description: YH001 + Toripalimab
Study: NCT06419738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral treatment (CBT)
Description: Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy combined with CBT (LLLT+CBT)
Description: LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint combined with CBT (OS+CBT)
Description: Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
Study: NCT06015464

Intervention type: DRUG
Intervention: Orelabrutinib
Description: Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP

Intervention type: DRUG
Intervention: Orelabrutinib
Description: Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
Study: NCT02255903

Intervention type: OTHER
Intervention: ultrasound and Doppler examination
Description: ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion

Intervention type: OTHER
Intervention: ultrasound and Doppler examination
Description: ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
Study: NCT04639531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orientation and Mobility Training with VR-IOMSs
Description: Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation and Mobility Training with COMS
Description: Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Orientation and Mobility Training
Description: No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
Study: NCT05182866

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
Study: NCT05472753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Treatment, DCOOP Product, Hydroxytyrosol extract
Description: Intervention group will receive a nutritional formula from DCOOP (Spain).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Treatment,Indukern product, Curcumin and selenium extract
Description: Intervention group will receive a nutritional formula from Indukern (Spain).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Treatment
Description: Control group will receive a placebo (product loading substance)
Study: NCT06319378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin 25 mg sod
Description: psilocybin 25 mg sod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psilocybin 1 mg sod
Description: active placebo
Study: NCT05708170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 200 MG
Description: Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
Study: NCT05795348

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalised Musculoskeletal Modeling
Description: Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
Study: NCT05934357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber
Description: The intervention treatment will contain fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control treatment will contain corn meal.
Study: NCT04841538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
Study: NCT05881551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eEgg
Description: In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.

Intervention type: OTHER
Group type: OTHER
Intervention: NRS
Description: Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
Study: NCT06637163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Carboplatin + Radiotherapy
Description: Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
Study: NCT06640296

Intervention type: DRUG
Intervention: Liposomal Amphotericin B (LAmB)
Description: collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
Study: NCT06447103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, and CT of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI of the brain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Girentuximab
Description: Given IV
Study: NCT05905146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical plan
Description: multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
Study: NCT05607472

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood samples for bio collection

Intervention type: OTHER
Group type: OTHER
Intervention: questionnary of health estate during 18 month
Description: clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
Study: NCT05599165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: signal processing on consonant recognition
Description: Consonant recognition will be measured in noise without any signal processing.